Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus SULTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus SULTRIN.
SULTEN-10 vs SULTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Sultrin (sulfanilamide, sulfathiazole, sulfacetamide) is a triple sulfonamide combination that acts as a bacteriostatic agent. It inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for the active site of dihydropteroate synthase, thereby blocking the conversion of PABA to dihydrofolic acid. This disrupts nucleic acid synthesis in susceptible bacteria.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
Intravaginal administration: one applicatorful (approximately 5 g) of Sultrin Triple Sulfa Cream (containing sulfathiazole, sulfacetamide, and sulfabenzamide) intravaginally once or twice daily for 4 to 7 days. Oral: Not applicable.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Terminal half-life 8-12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic